Studies Actively Enrolling

• 10134: Close Assessment and Testing for Chronic GVHD (The CATCH Study)
  
• 10360: Predicting the Quality of Response to Specific Treatments (PQRST)
• 10391: Long-Term Oral Health Outcomes in the Chronic GVHD Consortium
• 10421: Randomized, placebo-controlled, phase II trial examining ustekinumab for prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation
• 10582: Early measurement of ST2 as a prognostic biomarker for future occurrence of acute GVHD II-IV in a prospective multisite study 

Studies Open for Follow-Up and Data Analysis Only

• 2192: Improving Outcomes Assessment in Chronic Graft versus Host Disease
• 2207: Late Effects of Stem Cell Transplantation
• 2342: Longitudinal Study of Immune Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation
• 2710: Chronic GVHD Response Measures Validation
• 2732: Chronic GVHD Response Measures Validation: Control Cohort
• 8735: A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease after a Failure of Systemic Clucocorticoids
• 8708: Multi-Site Randomized Trial of Inpatient Palliative Care for Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation
• 8771: A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-vs-Host Disease
• 9421: Patient Feedback about the Chronic Graft versus Host Disease Symptom Scale
• 9643: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease
• 9926: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease
• 9962: Randomized Feasibility Study of Discontinuation versus Continuation of Immunosuppressive Therapy (IST) in Patients with Chronic Graft Versus Host Disease (GHVD)
• 10068: A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Subjects with Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Prior Therapy, Including Ibrutinib
• 10608: AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
• 10866: Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213

Closed Clinical Trials

• 2109: Physician-patient Communication in Hematologic Malignancies
• 2160: Advance Care Planning and Symptom Management in Stem Cell Transplantation
• 2250: A Randomized Multicenter Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies
• 2317: Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults
• 2321: A Randomized Placebo-Controlled, Double-Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
• 2341: Personality and Patient Self-Reported Measures
• 2343: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation 
• 2367: Targeted Therapy of Bronchiolitis Obliterans Syndrome (FAM for BOS) 
• 2436: Biomarkers in Chronic Graft versus Host Disease
• 2443 (BMT CTN 0902): A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients
• 2563: Costs of HCT
• 2617: A Phase II Study of Bandage Lenses for Ocular Graft-versus-host Disease after Allogeneic Hematopoietic Cell Transplantation
• 2659: Feasibility of Implementing Pre-Transplant Evaluation by the Supportive Care Team for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies
• 2663: Provider Survey on Frequently Asked Questions About the National Institutes of Health (NIH) Consensus for Chronic Graft-versus-Host Disease (GVHD)
• 2676: Survey of Transplant Clinicians Regarding Diagnosis, Grading, and Management of Chronic GVHD
• 8699: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Diseasse (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
• 9228: Carfilzomib for Treatment of Chronic Graft versus Host Disease
• 9292: Ixazomib for Treatment of Chronic Graft versus Host Disease
• 9514: Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft versus Host Disease
• 9728: Test-Retest Reliability of the Lee Chronic GVHD Symptom Scale